A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology

Status unconfirmed · Phase 3

Conditions studied: Dementia, Alzheimer's Disease

In brief

To Determine the the Efficacy and Safety of \[18F\]NAV4694 PET for Detection of Cerebral β-Amyloid When Compared With Postmortem Histopathology

Key facts

Study ID

NCT01886820

Run by

Navidea Biopharmaceuticals

People needed

290

Starts

2013-06-01

Expected to finish

2018-09-01

Last updated by the study team

2017-07-26

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female subjects will be at least 21 years of age.
• Subjects will have a life expectancy of approximately 6 months
• Subject health is adequate as determined by the investigator to receive [18F]NAV4694
• Female subjects will not be of child-bearing potential or will have a negative urine pregnancy test on day of [18F]NAV4694 injection.
• Must exhibit adequate visual, auditory, and communication capabilities to enable compliance with study procedures. This includes being able to lie down flat in the MRI or CT and PET scanner for a period of approximately 1 hour.
• Subjects must be willing to donate their brains for post mortem examination upon death (this consent can be obtained in the manner specific to the country/region involved).
• Subjects have been fully informed about the study, including provisions of the Health Insurance Portability and Accountability Act (HIPAA), as applicable, and informed consent or assent has been signed and dated (with time) by the subject and/or the subject's legally acceptable representative (LAR) (for individuals with dementia).

You may not qualify if…

• Scheduled for surgery and/or another invasive procedure within the time period of up to 7 days after [18F]NAV4694 injection.
• Has severe cerebral macrovascular (i.e., multi-stroke) disease or brain tumor (metastasis/brain cancer) as verified by MRI that prohibits sampling of the required pre-specified ROIs.
• Has any history of any transmissible spongiform encephalopathy (prion disease).
• Has received any contrast material (X-ray, MRI) or radiopharmaceutical within 48 hours prior to, or a therapeutic radiopharmaceutical (e.g., 131-I) within 10 days prior to, or any radiopharmaceutical administration within 10 radioactive half-lives prior to the administration of the investigational product or for whom administration of such substances is planned within 7 days after investigational product administration.
• Is allergic to the investigational product or any of its constituents.

Where it is running

• Banner Sun Health Research Institute — Sun City, Arizona, United States
• University of California San Diego — La Jolla, California, United States
• Neuropsychiatric Research Center of Southwest Florida — Fort Myers, Florida, United States
• Mount Sinai Medical Center of Florida — Miami Beach, Florida, United States
• Galiz Research — Miami Springs, Florida, United States
• Compass Research — Orlando, Florida, United States
• Physicians Care Clinical Research — Sarasota, Florida, United States
• Rush University Medical Center — Chicago, Illinois, United States
• Southern Illinois University School of Medicine — Springfield, Illinois, United States
• Biomedical Research Foundation — Shreveport, Louisiana, United States
• Las Vegas Radiology — Las Vegas, Nevada, United States
• Albert Einstein College of Medicine — The Bronx, New York, United States
• The University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States
• Wake Forest Baptist Health-Gerontology — Winston-Salem, North Carolina, United States
• Valley Medical Center — Centerville, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.